A new study published in The Lancet Digital Health suggests that biological age of different organs could predict a person's risk of diseases such as cancer, dementia, and heart disease than their actual chronological age. The research analyzed long-term data from Whitehall II study, which had been followed by over 10,000 British adults for more than 35 years.

The blood plasma samples were collected between 1997 and 1999 from participants between ages 45 to 69. Researchers have now examined a follow up data from 6,235 participants, who were by then aged 65 to 89. This was done to see how aging of specific organ may correlate with the development of diseases over two decades.

What Organs Were Studied?

The study measured the biological age of nine key organs, including:

• Heart
• Blood vessels
• Liver
• Immune system
• Pancreas
• Kidneys
• Lungs
• Intestines
• Brain

The researchers were able to find that different organs aged at different rates in different people. In many of the cases multiple organs showed signs of faster aging within the same individual. What is important to note is that those with accelerated aging in certain organs had a higher risk of developing 30 out of the 40 age-related diseases the study had tracked.

Organ Aging And Disease Risk

Some organ-disease connections were expected—people with rapidly aging lungs were more likely to develop respiratory diseases, and those with aging kidneys had an increased risk of kidney-related conditions. However, the study also found less obvious associations.

For example, individuals with fast-aging kidneys were more prone to diseases in other organs, such as the liver and pancreas. Additionally, multiple fast-aging organs were linked to an increased risk of kidney disease.

One of the most surprising findings was that dementia risk was not best predicted by an aging brain but rather by the immune system’s biological age. This suggests that factors such as chronic inflammation and immune health may play a critical role in neurodegenerative diseases.

What Is Organ Specific Blood Tests?

The study also highlights the important of the potential of developing blood tests that could assess the biological age of specific organs. Unlike previous complex methods that measured the organ health, this new approach could make things simple to detect early signs of disease.

The leader author of the study Mika Kivimaki, who is also a professor at the University College London's Faculty of Brain sciences pointed out that such tests could be helpful when it comes to guiding personalized healthcare. In a news release, Kivimaki said, "They could advise whether a person needs to take better care of a particular organ and potentially provide an early warning signal that they may be at risk of a particular disease."

The study reinforces the idea that aging does not affect all organs equally and that looking beyond chronological age could offer better insights into disease prevention. By understanding which organs are aging more rapidly, medical professionals may be able to recommend targeted interventions for individuals at higher risk of specific conditions. Future advancements in organ-specific blood testing could revolutionize how we detect and manage age-related diseases, potentially leading to more personalized healthcare strategies.

Many people carry the thalassemia gene without knowing it because they may not have any symptoms. A simple carrier screening test before pregnancy can help couples understand risks and make informed decisions while planning parenthood.

Importance of Genetic Screening

Parenthood planning today is not only about financial preparation or healthy lifestyle changes, but also about understanding genetic health risks that can impact the child’s future. And one such condition that tends to go unnoticed is thalassemia carrier status.

Did you know? Many individuals discover they are carriers only after facing difficulties during pregnancy or after the birth of a child with thalassemia major.

What Is Thalassemia?

Thalassemia is an inherited blood disorder that affects the production of hemoglobin, the protein in red blood cells that carries oxygen throughout the body. People who are carriers usually live normal and healthy lives and may not experience major symptoms. Because of this, many remain unaware of their carrier status for years.

However, it becomes a matter of concern when both partners are carriers of the thalassemia gene. In such cases, there is a huge risk that the child may inherit thalassemia major, a severe condition that may require lifelong blood transfusions, regular hospital visits, medications, and continuous medical care.

Why Thalassemia Often Goes Undetected

These are some of the challenges faced by families: So, challenges are that the thalassemia carrier status is often detected very late. Mild tiredness or anemia may be ignored or mistaken for iron deficiency, and many will not seek help.

So, couples do not consider genetic testing before marriage or pregnancy because they feel healthy and have no family history of the disease. When a child is born with thalassemia major, families may face stress, anxiety, repeated hospital visits, financial burden, and long-term treatment responsibilities. The condition can also affect the child’s growth, immunity, and overall quality of life.

The Need For Awareness And Early Action

This is why screening is important for couples: Carrier screening is a simple blood test that helps identify whether a person carries the thalassemia gene. If one partner tests positive, the other partner is advised to get tested as well.

Early screening before pregnancy helps couples understand their risks and explore available options with proper guidance. Thalassemia carrier screening is a small step that can make a major difference in parenthood planning.

Increasing awareness and encouraging timely testing can help families make informed decisions and reduce the burden of severe thalassemia in future generations. So, it is imperative to go for timely screening as advised by the expert and improve the quality of life.

Mental health issues among doctors remain a serious but rarely discussed concern within the medical community, said Dr. Cyriac Abby Philips, popularly known on social media as the LiverDoc.

In an exclusive interaction with HealthandMe, the noted hepatologist highlighted the rising cases of burnout, depression, and suicide among healthcare professionals and the urgent need to address them.

He stated that doctors are among the major communities affected by mental health disorders, although the topic is often ignored within the profession.

“We have had very senior doctors die by suicide because of burnout,” he said, citing incidents involving highly successful doctors recently reported from parts of India, including Kerala.

Mental Health Of Doctors Impacts Patient Care

Liver Doc stressed that addressing doctors’ mental health is as important as treating patients’ mental health.

“A doctor who has good mental health will be a much better ally for the patient when it comes to treatment,” he said.

He also urged the medical community and regulatory authorities to introduce more interventions and support systems to prevent burnout and mental health disorders among doctors.

According to him, the emotional burden of treating critically ill patients and witnessing deaths regularly can deeply affect healthcare professionals.

“It’s depressing to treat patients and see them die. It’s depressing to see another human die,” he said.

The expert noted that doctors should find ways to openly discuss and process emotional stress and mental health struggles.

New Book On Burnout And Emotional Stress

Dr. Philips also addressed the issue in his recently released book, The Liver Doctor: Stories of Love, Loss and Regeneration.

He told HealthandMe that he has “very thoroughly and in very raw format addressed in the book” the mental health disorders affecting doctors, as it directly impacts patient care.

“Like every other doctor, I have also gone through that, and it's depressing to treat patients and see them die. I have this book to channelize that, and I feel less burdened when I do that, but other doctors also should find ways to do this. So this book also tells doctors to be more open about their mental health,” he said.

Deep Burnout Among Doctors

Doctors in teaching hospitals often endure long, unregulated shifts with little time for rest, especially during residency. Such exhausting work conditions not only increase the risk of medical errors but also significantly contribute to burnout, emotional exhaustion, and mental health problems among young doctors.

As per a recent nationwide survey on doctors’ mental health and morale, nine in ten doctors said they would not want their children to become physicians.

Also read: Global Mental Disorders Double In 33 Years, Affecting 1.2 Billion People: Study

The study, conducted by the Debabrata Mitalee Auro Foundation, surveyed 1,208 doctors across metropolitan cities and smaller towns over six months and found deep levels of burnout, fear of violence, and rising medico-legal anxiety among medical professionals.

Parliamentary Panel Flags Excessive Duty Hours

Further, the Parliamentary Standing Committee on Health and Family Welfare also raised concerns over “excessive continuous duty hours” for junior and senior resident doctors in April.

In its latest report, the panel warned that fatigue-driven errors and burnout could compromise care.

The Panel recommended that the government introduce and strictly enforce a formal “Clinical Duty Hours Regulation” policy. This would mandate fixed rest periods and monitored duty rosters, with oversight mechanisms to prevent violations.

India’s cell and gene therapy ecosystem is beginning to attract a different kind of attention that is driven not just by healthcare demand, but by proprietary science and platform-led innovation.

For investors, however, the larger story may not be the funding round itself. It may be the problem the company is trying to solve.

CAR-T therapies have transformed outcomes for several difficult-to-treat blood cancers globally. But despite strong initial responses, relapse remains one of the field’s biggest limitations. One reason is antigen escape, which means cancer cells can change the markers that therapies use to identify them, making them harder to detect over time.

In an analysis of 4,129 CAR-T treated patients, relapse remained a substantial issue after single-target therapy, with 42.1% of relapses associated with loss of the CD19 target itself. The finding points to a larger issue: precision may not be enough if therapies lose visibility over time.

The response increasingly appears to be a move toward multi-target and more durable platforms. A bispecific CAR-T platform designed to recognize more than one tumor marker, to reduce relapse is crucial.

The science itself is becoming increasingly platform-oriented. Beyond broader targeting, recent work explored why immune cells themselves lose effectiveness over time and identified pathways associated with stronger persistence and memory. While still early, the broader implication is that future therapies may need to be designed not only to attack disease, but also to remain active longer.

For India, that creates a larger opportunity. Historically, advanced therapies such as CAR-T have remained expensive and heavily dependent on technologies developed elsewhere. The aim is to significantly reduce treatment costs while building indigenous capabilities across design and manufacturing.

The shift matters because biotech investing is increasingly moving beyond services and generics toward intellectual property and platform science. The transition from bedside observations to translational platforms may be where the next phase of healthcare innovation and investment gets built.